In February 2021, the EMA further detailed the procedure to be followed in order to control and limit the concentrations of nitrosamine impurities in medicinal products. Where scientifically justified and in line with the provisions of Swiss legislation on therapeutic products, Swissmedic aims to harmonise its requirements with those of European authorities.
May 7, 2021